2-(4-Tert-butyl-2,6-dimethyl-3-hydroxybenzyl)-2-imidazoline
3-[(4,5-dihydro-1H-Imidazol-2-yl)methyl]-6-(1,1-dimethylethyl)-2,4-dimethylphenol
6-t-Butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
6-Tert-butyl-3-(2-imidazolin-2-ylmethyl)-2,4-dimethylphenol
Oximetazolinum
Oxymetazolina
Oxymetazolinum
Oxymethazoline
Oxymetozoline

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Oxymetazoline hydrochloride	K89MJ0S5VY	2315-02-8	BEEDODBODQVSIM-UHFFFAOYSA-N

Prescription Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
Clirol Nasal Spray	Spray	0.5 %	Nasal	Complex Pharma Inc.	Not applicable	Not applicable
Rhofade	Cream	10 mg/g	Topical	Allergan	2017-01-18	Not applicable

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
12 Hour Nasal	Spray	.05 g/100mL	Nasal	Select Brands Distributors	2000-03-01	Not applicable
12 Hour Nasal	Spray	.05 g/100mL	Nasal	Meijer Distribution	2015-05-06	Not applicable
12 Hour Nasal	Spray	.05 g/100mL	Nasal	Healthlife of Usa	2018-01-02	Not applicable
12 Hour Nasal	Spray	.05 g/100mL	Nasal	Altaire Pharmaceuticals Inc.	2001-06-01	Not applicable
12 Hour Original Nasal Decongestant	Liquid	50 mg/100mL	Nasal	Faria Llc Dba Sheffield Pharmaceutcials	2014-05-30	Not applicable
12 Hour Original Nasal Decongestant	Liquid	50 mg/100mL	Nasal	Preferreed Pharmaceuticals Inc.	2018-01-02	Not applicable
7 Select Nasal	Spray	.05 g/100mL	Nasal	7 Eleven	2014-08-05	Not applicable
7 Select Original Nasal	Spray	.05 g/mL	Nasal	7 Eleven	2016-10-04	Not applicable
Afrin	Spray	.5 mg/mL	Topical	Navajo Manuracturing Company	2017-12-04	Not applicable
Afrin Cold	Spray	0.05 mg	Nasal	Schering Plough	2002-09-28	2006-08-01

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
Kovanaze	Oxymetazoline hydrochloride (.5 mg/mL) + Tetracaine hydrochloride (30 mg/mL)	Spray	Nasal	St. Renatus	2016-09-01	Not applicable

International/Other Brands

Afrin / Dristan 12-Hour / Duramist Plus / Genasal Nasal Spray Up to 12 Hour Relief / Iliadin / Neo-Synephrine 12 Hour Spray / Nezeril / Nostrilla 12 Hour Nasal Decongestant / OcuClear / Vicks Sinex 12 Hour Nasal Spray / Vicks Sinex 12 Hour Ultra Fine Mist for Sinus Relief

Categories

UNII

8VLN5B44ZY

CAS number

1491-59-4

Weight

Average: 260.3746
Monoisotopic: 260.1888634

Chemical Formula

C₁₆H₂₄N₂O

InChI Key

WYWIFABBXFUGLM-UHFFFAOYSA-N

InChI

InChI=1S/C16H24N2O/c1-10-8-13(16(3,4)5)15(19)11(2)12(10)9-14-17-6-7-18-14/h8,19H,6-7,9H2,1-5H3,(H,17,18)

IUPAC Name

6-tert-butyl-3-(4,5-dihydro-1H-imidazol-2-ylmethyl)-2,4-dimethylphenol

SMILES

CC1=CC(=C(O)C(C)=C1CC1=NCCN1)C(C)(C)C

Pharmacology

Indication

For treatment of nasal congestion and redness associated with minor irritations of the eye

Associated Conditions

Pharmacodynamics

Oxymetazoline a adrenergic alpha-agonists, direct acting sympathomimetic used as a vasoconstrictor to relieve nasal congestion The sympathomimetic action of oxymetazoline constricts the smaller arterioles of the nasal passages, producing a prolonged (up to 12 hours), gentle and decongesting effect. Oxymetazoline elicits relief of conjunctival hyperemia by causing vasoconstriction of superficial conjunctival blood vessels. The drug's action has been demonstrated in acute allergic conjunctivitis and in chemical (chloride) conjunctivitis.

Mechanism of action

Oxymetazoline is a direct acting sympathomimetic amine, which acts on alpha-adrenergic receptors in the arterioles of the conjunctiva and nasal mucosa. It produces vasoconstriction, resulting in decreased conjunctival congestion in ophthalmic. In nasal it produces constriction, resulting in decreased blood flow and decreased nasal congestion.

Target	Actions	Organism
AAlpha-1A adrenergic receptor	agonist	Human
AAlpha-2A adrenergic receptor	agonist partial agonist	Human
UAlpha-2C adrenergic receptor	agonist	Human
UAlpha-2B adrenergic receptor	binder	Human
UAlpha-1B adrenergic receptor	agonist	Human
UAlpha-1D adrenergic receptor	agonist	Human

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Not Available

Route of elimination

Not Available

Half life

Not Available

Clearance

Not Available

Toxicity

Not Available

Affected organisms

Humans and other mammals

Pathways

Not Available

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylamphetamine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.	Experimental
3-isobutyl-1-methyl-7H-xanthine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3-isobutyl-1-methyl-7H-xanthine.	Experimental
3,4-Methylenedioxyamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 3,4-Methylenedioxyamphetamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 4-Bromo-2,5-dimethoxyamphetamine.	Experimental, Illicit
6-O-benzylguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 6-O-benzylguanine.	Investigational
7-Deazaguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7-Deazaguanine.	Experimental
7,9-Dimethylguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 7,9-Dimethylguanine.	Experimental
8-azaguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-azaguanine.	Experimental
8-chlorotheophylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 8-chlorotheophylline.	Approved
9-Deazaguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Deazaguanine.	Experimental
9-Methylguanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with 9-Methylguanine.	Experimental
Acebutolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acebutolol.	Approved, Investigational
Acefylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acefylline.	Experimental
Acepromazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Acepromazine.	Approved, Vet Approved
Acyclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Acyclovir.	Approved
Ajulemic acid	The risk or severity of Tachycardia can be increased when Ajulemic acid is combined with Oxymetazoline.	Investigational
Alfuzosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alfuzosin.	Approved, Investigational
Alprenolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Alprenolol.	Approved, Withdrawn
Amineptine	Amineptine may increase the vasopressor activities of Oxymetazoline.	Illicit, Withdrawn
Amitriptyline	Amitriptyline may increase the vasopressor activities of Oxymetazoline.	Approved
Amitriptylinoxide	Amitriptylinoxide may increase the vasopressor activities of Oxymetazoline.	Approved, Investigational
Amoxapine	Amoxapine may increase the vasopressor activities of Oxymetazoline.	Approved
Amphetamine	The risk or severity of adverse effects can be increased when Amphetamine is combined with Oxymetazoline.	Approved, Illicit, Investigational
Anisodamine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Anisodamine.	Investigational
Aripiprazole	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole.	Approved, Investigational
Aripiprazole lauroxil	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Aripiprazole lauroxil.	Approved, Investigational
Arotinolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Arotinolol.	Investigational
Asenapine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Asenapine.	Approved
Atenolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Atenolol.	Approved
Atomoxetine	The risk or severity of hypertension can be increased when Atomoxetine is combined with Oxymetazoline.	Approved
Azathioprine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Azathioprine.	Approved
Bamifylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bamifylline.	Experimental
Befunolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Befunolol.	Experimental
Benmoxin	Benmoxin may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Benzphetamine	The risk or severity of adverse effects can be increased when Benzphetamine is combined with Oxymetazoline.	Approved, Illicit
Benzylpenicilloyl Polylysine	Oxymetazoline may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Betaxolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Betaxolol.	Approved, Investigational
Bevantolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bevantolol.	Approved
Bisoprolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bisoprolol.	Approved
Bopindolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bopindolol.	Approved
Brexpiprazole	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Brexpiprazole.	Approved, Investigational
Bromocriptine	Bromocriptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Investigational
Bromotheophylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bromotheophylline.	Approved
Bucindolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bucindolol.	Investigational
Bufuralol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bufuralol.	Experimental, Investigational
Bufylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Bufylline.	Experimental
Bunazosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bunazosin.	Investigational
Bupranolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Bupranolol.	Approved
Butriptyline	Butriptyline may increase the vasopressor activities of Oxymetazoline.	Approved
Cabergoline	Cabergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Cafedrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Cafedrine.	Investigational
Caffeine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Caffeine.	Approved
Cannabidiol	The risk or severity of Tachycardia can be increased when Cannabidiol is combined with Oxymetazoline.	Approved, Investigational
Caroxazone	Caroxazone may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Carteolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Carteolol.	Approved
Carvedilol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Carvedilol.	Approved, Investigational
Celiprolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Celiprolol.	Approved, Investigational
Chlorphentermine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Chlorphentermine.	Illicit, Withdrawn
Chlorpromazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Chlorpromazine.	Approved, Investigational, Vet Approved
Clenbuterol	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Clenbuterol.	Approved, Investigational, Vet Approved
Clomipramine	Clomipramine may increase the vasopressor activities of Oxymetazoline.	Approved, Investigational, Vet Approved
Cloranolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Cloranolol.	Experimental
Clozapine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Clozapine.	Approved
CP-945598	The risk or severity of Tachycardia can be increased when CP-945598 is combined with Oxymetazoline.	Investigational
Cyclobenzaprine	Cyclobenzaprine may increase the vasopressor activities of Oxymetazoline.	Approved
Dapiprazole	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dapiprazole.	Approved
Desipramine	Desipramine may increase the vasopressor activities of Oxymetazoline.	Approved, Investigational
Desvenlafaxine	Desvenlafaxine may increase the tachycardic activities of Oxymetazoline.	Approved, Investigational
Dextroamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dextroamphetamine.	Approved, Illicit
Dibenzepin	Dibenzepin may increase the vasopressor activities of Oxymetazoline.	Experimental
Diethylpropion	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Diethylpropion.	Approved, Illicit
Dihydroergocornine	Dihydroergocornine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Dihydroergocristine	Dihydroergocristine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Experimental
Dihydroergocryptine	Dihydroergocryptine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Experimental
Dihydroergotamine	Dihydroergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Investigational
Dimetacrine	Dimetacrine may increase the vasopressor activities of Oxymetazoline.	Approved, Withdrawn
Dobutamine	The risk or severity of adverse effects can be increased when Dobutamine is combined with Oxymetazoline.	Approved
Dopamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Dopamine.	Approved
Dosulepin	Dosulepin may increase the vasopressor activities of Oxymetazoline.	Approved
Doxazosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Doxazosin.	Approved
Doxepin	Doxepin may increase the vasopressor activities of Oxymetazoline.	Approved, Investigational
Doxofylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Doxofylline.	Approved, Investigational
Dronabinol	The risk or severity of Tachycardia can be increased when Dronabinol is combined with Oxymetazoline.	Approved, Illicit
Dronedarone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Dronedarone.	Approved
Droperidol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Droperidol.	Approved, Vet Approved
Duloxetine	Duloxetine may increase the tachycardic activities of Oxymetazoline.	Approved
Entecavir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Entecavir.	Approved, Investigational
Epanolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Epanolol.	Experimental
Ephedrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ephedrine.	Approved
Epinephrine	The risk or severity of adverse effects can be increased when Epinephrine is combined with Oxymetazoline.	Approved, Vet Approved
Ergoloid mesylate	Ergoloid mesylate may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Ergonovine	Ergonovine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Ergotamine	Ergotamine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Esatenolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esatenolol.	Experimental
Esmolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Esmolol.	Approved
Etamiphylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etamiphylline.	Experimental
Etilefrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Etilefrine.	Withdrawn
Fenethylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenethylline.	Approved
Fenoterol	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenoterol.	Approved, Investigational
Fenozolone	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Fenozolone.	Experimental
Fentanyl	The therapeutic efficacy of Fentanyl can be decreased when used in combination with Oxymetazoline.	Approved, Illicit, Investigational, Vet Approved
Flupentixol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Flupentixol.	Approved, Investigational, Withdrawn
Furafylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Furafylline.	Experimental
Furazolidone	Furazolidone may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational, Vet Approved
Ganciclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ganciclovir.	Approved, Investigational
Gepefrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Gepefrine.	Experimental
Guanine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Guanine.	Experimental
GW842166	The risk or severity of Tachycardia can be increased when GW842166 is combined with Oxymetazoline.	Investigational
Harmaline	Harmaline may increase the hypertensive activities of Oxymetazoline.	Experimental
Hyaluronidase	Hyaluronidase may increase the vasoconstricting activities of Oxymetazoline.	Approved, Investigational
Hydracarbazine	Hydracarbazine may increase the hypertensive activities of Oxymetazoline.	Experimental
Hydroxyamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hydroxyamphetamine.	Approved
Hypoxanthine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Hypoxanthine.	Experimental
Ibipinabant	The risk or severity of Tachycardia can be increased when Ibipinabant is combined with Oxymetazoline.	Investigational
Iloperidone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Iloperidone.	Approved
Imipramine	Imipramine may increase the vasopressor activities of Oxymetazoline.	Approved
Imipramine oxide	Imipramine oxide may increase the vasopressor activities of Oxymetazoline.	Experimental
Indenolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indenolol.	Withdrawn
Indoramin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Indoramin.	Withdrawn
Iobenguane	Oxymetazoline can cause a decrease in the absorption of Iobenguane resulting in a reduced serum concentration and potentially a decrease in efficacy.	Approved, Investigational
Iofetamine I-123	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Iofetamine I-123.	Approved
Iprindole	Iprindole may increase the vasopressor activities of Oxymetazoline.	Experimental
Iproniazid	Iproniazid may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Isocarboxazid	Isocarboxazid may increase the hypertensive activities of Oxymetazoline.	Approved
Isoprenaline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoprenaline.	Approved, Investigational
Isoxsuprine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Isoxsuprine.	Approved, Withdrawn
Labetalol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Labetalol.	Approved
Landiolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Landiolol.	Investigational
Levobetaxolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Levobetaxolol.	Approved, Investigational
Levobunolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Levobunolol.	Approved
Levomilnacipran	Levomilnacipran may increase the tachycardic activities of Oxymetazoline.	Approved, Investigational
Linezolid	The risk or severity of hypertension can be increased when Linezolid is combined with Oxymetazoline.	Approved, Investigational
Lisdexamfetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisdexamfetamine.	Approved, Investigational
Lisofylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lisofylline.	Investigational
Lisuride	Lisuride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Investigational
Lobucavir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Lobucavir.	Investigational
Lofepramine	Lofepramine may increase the vasopressor activities of Oxymetazoline.	Experimental
Lysergic Acid Diethylamide	Lysergic Acid Diethylamide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Illicit, Investigational, Withdrawn
Mebanazine	Mebanazine may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Mefenorex	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mefenorex.	Experimental
Melitracen	Melitracen may increase the vasopressor activities of Oxymetazoline.	Experimental, Investigational
Mephedrone	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephedrone.	Investigational
Mephentermine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Mephentermine.	Approved
Mepindolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mepindolol.	Experimental
Metaraminol	The risk or severity of adverse effects can be increased when Metaraminol is combined with Oxymetazoline.	Approved, Investigational
Metergoline	Metergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Experimental
Methamphetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methamphetamine.	Approved, Illicit
Methotrimeprazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Methotrimeprazine.	Approved, Investigational
Methoxamine	The risk or severity of adverse effects can be increased when Methoxamine is combined with Oxymetazoline.	Approved, Investigational
Methoxyphenamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Methoxyphenamine.	Experimental
Methylene blue	Methylene blue may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational
Methylergometrine	Methylergometrine may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Methysergide	Methysergide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved
Metipranolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metipranolol.	Approved
Metoprolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Metoprolol.	Approved, Investigational
Mianserin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Mianserin.	Approved, Investigational
Midodrine	The risk or severity of adverse effects can be increased when Midodrine is combined with Oxymetazoline.	Approved
Midomafetamine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Midomafetamine.	Experimental, Illicit, Investigational
Milnacipran	Milnacipran may increase the tachycardic activities of Oxymetazoline.	Approved, Investigational
Minaprine	Minaprine may increase the hypertensive activities of Oxymetazoline.	Approved
Mirtazapine	Mirtazapine may decrease the antihypertensive activities of Oxymetazoline.	Approved
MMDA	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with MMDA.	Experimental, Illicit
Moclobemide	Moclobemide may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational
Nabilone	The risk or severity of Tachycardia can be increased when Nabilone is combined with Oxymetazoline.	Approved, Investigational
Nabiximols	The risk or severity of Tachycardia can be increased when Nabiximols is combined with Oxymetazoline.	Approved, Investigational
Nadolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nadolol.	Approved
Nebivolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nebivolol.	Approved, Investigational
Nefazodone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nefazodone.	Approved, Withdrawn
Nialamide	Nialamide may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Nicardipine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Nicardipine.	Approved, Investigational
Nicergoline	Nicergoline may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Investigational
Niguldipine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Niguldipine.	Experimental
Norepinephrine	The risk or severity of adverse effects can be increased when Norepinephrine is combined with Oxymetazoline.	Approved
Nortriptyline	Nortriptyline may increase the vasopressor activities of Oxymetazoline.	Approved
Nylidrin	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Nylidrin.	Approved
Octamoxin	Octamoxin may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Olanzapine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Olanzapine.	Approved, Investigational
Opipramol	Opipramol may increase the vasopressor activities of Oxymetazoline.	Investigational
Orciprenaline	The risk or severity of adverse effects can be increased when Orciprenaline is combined with Oxymetazoline.	Approved
Oxaprotiline	Oxaprotiline may increase the vasopressor activities of Oxymetazoline.	Experimental
Oxprenolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Oxprenolol.	Approved
Oxtriphylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Oxtriphylline.	Approved
Paliperidone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Paliperidone.	Approved
Palmidrol	The risk or severity of Tachycardia can be increased when Palmidrol is combined with Oxymetazoline.	Experimental, Nutraceutical
Pargyline	Pargyline may increase the hypertensive activities of Oxymetazoline.	Approved
Patent Blue	The risk or severity of hypotension can be increased when Patent Blue is combined with Oxymetazoline.	Approved
Peldesine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Peldesine.	Experimental, Investigational
Pemetrexed	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pemetrexed.	Approved, Investigational
Penbutolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Penbutolol.	Approved, Investigational
Penciclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Penciclovir.	Approved
Pentifylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentifylline.	Experimental
Pentoxifylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pentoxifylline.	Approved, Investigational
Pergolide	Pergolide may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Approved, Investigational, Vet Approved, Withdrawn
Phenelzine	Phenelzine may increase the hypertensive activities of Oxymetazoline.	Approved
Pheniprazine	Pheniprazine may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Phenmetrazine	The risk or severity of adverse effects can be increased when Phenmetrazine is combined with Oxymetazoline.	Approved, Illicit
Phenoxybenzamine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phenoxybenzamine.	Approved
Phenoxypropazine	Phenoxypropazine may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Phentermine	The risk or severity of adverse effects can be increased when Phentermine is combined with Oxymetazoline.	Approved, Illicit
Phentolamine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Phentolamine.	Approved
Phenylephrine	The risk or severity of adverse effects can be increased when Phenylephrine is combined with Oxymetazoline.	Approved
Phenylpropanolamine	The risk or severity of adverse effects can be increased when Phenylpropanolamine is combined with Oxymetazoline.	Approved, Vet Approved, Withdrawn
Pindolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pindolol.	Approved, Investigational
Pirlindole	Pirlindole may increase the hypertensive activities of Oxymetazoline.	Approved
Pivhydrazine	Pivhydrazine may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Pizotifen	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Pizotifen.	Approved
Practolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Practolol.	Approved
Prazosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Prazosin.	Approved
Prenalterol	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Prenalterol.	Experimental
Procaterol	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Procaterol.	Approved, Investigational
Promazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Promazine.	Approved, Vet Approved
Propafenone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propafenone.	Approved
Propentofylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Propentofylline.	Investigational
Propericiazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propericiazine.	Approved, Investigational
Propiomazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiomazine.	Approved
Propiverine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propiverine.	Approved, Investigational
Propranolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Propranolol.	Approved, Investigational
Protriptyline	Protriptyline may increase the vasopressor activities of Oxymetazoline.	Approved
Proxyphylline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Proxyphylline.	Experimental
Pseudoephedrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Pseudoephedrine.	Approved
Quetiapine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quetiapine.	Approved
Quinidine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Quinidine.	Approved, Investigational
Quinupramine	Quinupramine may increase the vasopressor activities of Oxymetazoline.	Experimental
Racepinephrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Racepinephrine.	Approved
Rasagiline	Rasagiline may increase the hypertensive activities of Oxymetazoline.	Approved
Rimonabant	The risk or severity of Tachycardia can be increased when Rimonabant is combined with Oxymetazoline.	Approved, Investigational
Risperidone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Risperidone.	Approved, Investigational
Ritobegron	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Ritobegron.	Investigational
Ritodrine	The risk or severity of adverse effects can be increased when Ritodrine is combined with Oxymetazoline.	Approved, Investigational
Safinamide	Safinamide may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational
Safrazine	Safrazine may increase the hypertensive activities of Oxymetazoline.	Withdrawn
Selegiline	Selegiline may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational, Vet Approved
Sibutramine	Sibutramine may increase the tachycardic activities of Oxymetazoline.	Approved, Illicit, Investigational, Withdrawn
Silodosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Silodosin.	Approved
SLV319	The risk or severity of Tachycardia can be increased when SLV319 is combined with Oxymetazoline.	Investigational
Sotalol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Sotalol.	Approved
Spironolactone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Spironolactone.	Approved
Surinabant	The risk or severity of Tachycardia can be increased when Surinabant is combined with Oxymetazoline.	Investigational
Synephrine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Synephrine.	Experimental
Talinolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Talinolol.	Investigational
Tamsulosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tamsulosin.	Approved, Investigational
Tedizolid phosphate	Tedizolid phosphate may increase the hypertensive activities of Oxymetazoline.	Approved
Terazosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Terazosin.	Approved
Terbutaline	The risk or severity of adverse effects can be increased when Terbutaline is combined with Oxymetazoline.	Approved
Terguride	Terguride may increase the hypertensive and vasoconstricting activities of Oxymetazoline.	Experimental
Tertatolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tertatolol.	Experimental
Tetryzoline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tetryzoline.	Approved
Theobromine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theobromine.	Approved, Investigational
Theodrenaline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Theodrenaline.	Investigational
Thioproperazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioproperazine.	Approved
Thioridazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Thioridazine.	Approved, Withdrawn
Tianeptine	Tianeptine may increase the vasopressor activities of Oxymetazoline.	Approved, Investigational
Timolol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Timolol.	Approved
Tolazoline	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Tolazoline.	Approved, Vet Approved
Toloxatone	Toloxatone may increase the hypertensive activities of Oxymetazoline.	Approved
Tramazoline	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tramazoline.	Investigational
Tranylcypromine	Tranylcypromine may increase the hypertensive activities of Oxymetazoline.	Approved, Investigational
Trazodone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trazodone.	Approved, Investigational
Tretoquinol	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tretoquinol.	Experimental
Trifluoperazine	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trifluoperazine.	Approved, Investigational
Trimazosin	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Trimazosin.	Experimental
Trimipramine	Trimipramine may increase the vasopressor activities of Oxymetazoline.	Approved
Tyramine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Tyramine.	Investigational, Nutraceutical
Urapidil	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Urapidil.	Investigational
Uric Acid	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Uric Acid.	Experimental, Investigational
Valaciclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valaciclovir.	Approved, Investigational
Valganciclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valganciclovir.	Approved, Investigational
Valomaciclovir	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Valomaciclovir.	Investigational
Venlafaxine	Venlafaxine may increase the tachycardic activities of Oxymetazoline.	Approved
Verapamil	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Verapamil.	Approved
WIN 55212-2	The risk or severity of Tachycardia can be increased when WIN 55212-2 is combined with Oxymetazoline.	Experimental
Xanthine	The risk or severity of adverse effects can be increased when Oxymetazoline is combined with Xanthine.	Experimental
Ziprasidone	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Ziprasidone.	Approved
Zuclopenthixol	The therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0015070
KEGG Compound: C07363
PubChem Compound: 4636
PubChem Substance: 46505622
ChemSpider: 4475
BindingDB: 30712
ChEBI: 7862
ChEMBL: CHEMBL762
Therapeutic Targets Database: DAP000235
PharmGKB: PA164748840
IUPHAR: 124
Guide to Pharmacology: GtP Drug Page
Drugs.com: Drugs.com Drug Page
Wikipedia: Oxymetazoline

ATC Codes

R01AA05 — Oxymetazoline

R01AB07 — Oxymetazoline

S01GA04 — Oxymetazoline

AHFS Codes

52:32.00 — Vasoconstrictors

MSDS

Download (74.6 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Autonomic Failure / Idiopathic orthostatic hypotension	1
1	Completed	Basic Science	Anaesthesia therapy	1
1	Completed	Basic Science	Acute Rhinitis	1
1	Completed	Treatment	Allergic Rhinitis (AR)	2
1	Completed	Treatment	Assess Pharmacokinetics of Ketorolac Tromethamine Intranasal and Assess Effects of a Oxymetazoline Hydrochloride on the PK of Ketorolac Tromethamine / Healthy Volunteers	1
1	Not Yet Recruiting	Treatment	Incontinence, Fecal	1
1, 2	Completed	Treatment	Incontinence, Fecal / Spinal Cord Injuries (SCI)	1
2	Completed	Prevention	Conjunctivitis, Seasonal Allergic	1
2	Completed	Treatment	Allergic Rhinitis (AR)	1
2	Completed	Treatment	Anaesthesia therapy	3
2	Completed	Treatment	Seasonal Allergic Rhinitis (SAR)	1
2	Withdrawn	Treatment	Anesthesia, Dental / Intranasal Drug Administration / Nasal Surgical Procedures	1
3	Completed	Treatment	Anaesthesia therapy	3
3	Completed	Treatment	Erythemas / Rosaceas	2
3	Completed	Treatment	Herpes Simplex Labialis	1
3	Recruiting	Treatment	Nasal Stuffiness / Rhinitis	1
3	Recruiting	Treatment	Rosaceas	1
3	Terminated	Treatment	Anaesthesia therapy	1
4	Completed	Treatment	Adenoidal Hypertrophy	1
4	Completed	Treatment	Allergic Rhinitis (AR)	1
4	Completed	Treatment	Nasal Obstruction Present Finding	1
4	Completed	Treatment	Rosaceas	1
4	Not Yet Recruiting	Other	Local Anesthetic Drug Adverse Reaction / Local Infiltration / Pulp Disease, Dental	1
4	Not Yet Recruiting	Treatment	Chronic Nasal Congestion / Sleep Apnea Syndrome	1
4	Recruiting	Prevention	Throat Disorder	1
4	Withdrawn	Treatment	Allergic Rhinitis (AR) / Rhinitis Medicamentosa / Tachyphylaxis	1
Not Available	Completed	Treatment	Adenoidectomy / Functional Endoscopic Sinus Surgery (FESS) / Turbinate Surgery	1
Not Available	Completed	Treatment	Blood Pressures / Nasal Bleeding	1
Not Available	Completed	Treatment	Nasal Obstruction	1
Not Available	Recruiting	Basic Science	Middle Ear Disease / Nasal Allergies	1
Not Available	Terminated	Treatment	Chronic Rhinitis	1

Pharmacoeconomics

Manufacturers

Schering plough healthcare products inc
Johnson and johnson group consumer companies

Packagers

Altaire Pharmaceuticals
Bayer Healthcare
Chain Drug
CVS Pharmacy
Palmetto Pharmaceuticals Inc.
Perrigo Co.
Pfizer Inc.
S&P Healthcare
Spectrum Pharmaceuticals
Target Corp.
Walgreen Co.
Wyeth Pharmaceuticals

Dosage forms

Form	Route	Strength
Liquid	Nasal	50 mg/100mL
Spray	Nasal	.05 g/mL
Spray	Topical	.5 mg/mL
Spray	Nasal	0.05 mg
Spray, metered	Nasal	.05 g/100mL
Spray, metered	Nasal	.05 mg/mL
Spray	Nasal	.05 g/100mL
Spray	Nasal	.2 mg/.4mL
Spray	Nasal	0.5 %
Spray	Nasal	.0005 g/mL
Spray	Nasal	.5 mg/mL
Spray	Nasal
Spray	Nasal	.05 mg/100mg
Liquid	Nasal	0.05 %
Spray	Nasal	0.05 %
Solution	Nasal	.5 mg/mL
Solution	Nasal	.05 g/100mL
Solution	Nasal	.05 mg/100mL
Solution / drops; spray	Nasal	.025 %
Spray	Nasal	5 g/100mL
Spray	Nasal	.05 mg/mL
Liquid	Topical	.05 g/100mL
Spray, metered	Nasal	.0005 mL/100mL
Spray, metered	Nasal	.05 mg/100mL
Solution / drops	Ophthalmic	.25 mg
Spray, metered	Nasal	0.05 %
Spray	Oral	.5 mg/mL
Spray, metered	Nasal	.2 mg/.4mL
Spray, metered	Nasal	.5 mg/mL
Cream	Topical	10 mg/g
Spray	Nasal	7.5 mg/15mL
Spray	Nasal	50 mg/100mL
Spray	Nasal	.05 mg/100mL
Spray	Nasal	.512 mg/mL
Spray	Nasal	.0005055 g/mL
Spray	Nasal	.000512 g/mL
Spray	Nasal	.0005095 g/mL
Liquid	Nasal	.05 %
Liquid	Ophthalmic	.25 mg/mL
Liquid	Ophthalmic	.025 %
Solution / drops	Ophthalmic	0.025 %
Spray	Nasal	.005 g/100mL
Solution	Nasal	0.05 %

Prices

Unit description	Cost	Unit
Oxymetazoline hcl powder	84.42USD	g
Afrin 0.05% nose spray	0.62USD	ml
Drixoral cold & allergy tablet sa	0.4USD	tablet
Afrin no drip sinus pump mist	0.38USD	ml
Oxymetazoline 0.05% spray	0.38USD	ml
Anefrin 0.05% nasal spray	0.37USD	ml
Afrin sinus spray	0.33USD	ml
Dristan long lasting mist	0.32USD	ml
Neo-synephrine 12 hour spray	0.28USD	ml
Visine long lasting eye drops	0.27USD	ml
12 hour nasal relief spray	0.24USD	ml
Dristan cold multi-symp tablet	0.23USD	tablet
Ocuclear eye drops	0.23USD	ml
CVS Pharmacy nasal spray 0.05%	0.22USD	ml
No drip 0.05% nasal spray	0.13USD	ml
Nasal spray 0.05%	0.06USD	ml
Sinus nasal spray	0.06USD	ml
Nasal decongestant 0.05% spray	0.03USD	ml
Pv nasal spray 0.05%	0.03USD	ml

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US8580282	No	2010-04-02	2030-04-02
US6413499	No	2000-03-20	2020-03-20
US9308191	No	2010-04-02	2030-04-02
US8883838	No	2011-12-01	2031-12-01
US7812049	No	2008-05-02	2028-05-02
US8420688	No	2004-08-02	2024-08-02
US9974773	No	2015-06-11	2035-06-11

Properties

State

Solid

Experimental Properties

Property	Value	Source
melting point (°C)	182 °C	PhysProp
logP	3.4	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.0515 mg/mL	ALOGPS
logP	3.7	ALOGPS
logP	3.03	ChemAxon
logS	-3.7	ALOGPS
pKa (Strongest Acidic)	10.91	ChemAxon
pKa (Strongest Basic)	10.15	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	2	ChemAxon
Polar Surface Area	44.62 Å²	ChemAxon
Rotatable Bond Count	3	ChemAxon
Refractivity	79.8 m³·mol^-1	ChemAxon
Polarizability	30.64 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	No	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9761
Blood Brain Barrier	-	0.5388
Caco-2 permeable	-	0.567
P-glycoprotein substrate	Substrate	0.8858
P-glycoprotein inhibitor I	Non-inhibitor	0.9477
P-glycoprotein inhibitor II	Non-inhibitor	0.6585
Renal organic cation transporter	Inhibitor	0.6039
CYP450 2C9 substrate	Non-substrate	0.7585
CYP450 2D6 substrate	Non-substrate	0.5707
CYP450 3A4 substrate	Non-substrate	0.5394
CYP450 1A2 substrate	Non-inhibitor	0.9045
CYP450 2C9 inhibitor	Non-inhibitor	0.9071
CYP450 2D6 inhibitor	Inhibitor	0.8931
CYP450 2C19 inhibitor	Non-inhibitor	0.9026
CYP450 3A4 inhibitor	Non-inhibitor	0.854
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.8682
Ames test	Non AMES toxic	0.7951
Carcinogenicity	Non-carcinogens	0.8923
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	4.4155 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8402
hERG inhibition (predictor II)	Non-inhibitor	0.7432

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Download (10.5 KB)

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available

Taxonomy

Description: This compound belongs to the class of organic compounds known as xylenols. These are aromatic compounds that contain a xylene moiety, which is a monocyclic benzene carrying exactly two methyl groups, and at least one hydroxyl group.
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Xylenes
Direct Parent: Xylenols
Alternative Parents: Phenylpropanes / m-Xylenes / Para cresols / Ortho cresols / Imidolactams / Imidazolines / Propargyl-type 1,3-dipolar organic compounds / Carboximidamides / Carboxamidines / Azacyclic compounds
show 3 more
Substituents: Xylenol / Phenylpropane / M-xylene / O-cresol / P-cresol / Phenol / Imidolactam / 2-imidazoline / Amidine / Carboxylic acid amidine
show 12 more
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: phenols, carboxamidine, imidazolines (CHEBI:7862)

Targets

Details1. Alpha-1A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist

General Function: Protein heterodimerization activity
Specific Function: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name: ADRA1A
Uniprot ID: P35348
Uniprot Name: Alpha-1A adrenergic receptor
Molecular Weight: 51486.005 Da

References

Yang HT, Endoh M: (+/-)-tamsulosin, an alpha 1A-adrenoceptor antagonist, inhibits the positive inotropic effect but not the accumulation of inositol phosphates in rabbit heart. Eur J Pharmacol. 1996 Oct 3;312(3):281-91. [PubMed:8894610]
Deplanne V, Galzin AM: Functional characterization of alpha-1-adrenoceptor subtypes in the prostatic urethra and trigone of male rabbit. J Pharmacol Exp Ther. 1996 Aug;278(2):527-34. [PubMed:8768700]
Shibata K, Taketani K: [Excitatory effect of noradrenaline on rat airway parasympathetic ganglion neurons]. Fukuoka Igaku Zasshi. 2001 Nov;92(11):377-83. [PubMed:11774707]
Furukawa K, Rosario DJ, Smith DJ, Chapple CR, Uchiyama T, Chess-Williams R: Alpha 1A-adrenoceptor-mediated contractile responses of the human vas deferens. Br J Pharmacol. 1995 Sep;116(1):1605-10. [PubMed:8564226]
Gonzalez-Espinosa C, Romero-Avila MT, Mora-Rodriguez DM, Gonzalez-Espinosa D, Garcia-Sainz JA: Molecular cloning and functional expression of the guinea pig alpha(1a)-adrenoceptor. Eur J Pharmacol. 2001 Aug 31;426(3):147-55. [PubMed:11527538]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	1.28	N/A	N/A	7908054
Ki (nM)	1.3	N/A	N/A	8935801
Ki (nM)	1.36	N/A	N/A	12954796
Ki (nM)	1.44	N/A	N/A	7908054
Ki (nM)	3.3	N/A	N/A	1353247
Ki (nM)	4.9	N/A	N/A	11408545
Ki (nM)	7.24	N/A	N/A	9605427
Ki (nM)	9.68	N/A	N/A	7996470

Details2. Alpha-2A adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Agonist
Partial agonist

General Function: Thioesterase binding
Specific Function: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is oxymetazo...
Gene Name: ADRA2A
Uniprot ID: P08913
Uniprot Name: Alpha-2A adrenergic receptor
Molecular Weight: 48956.275 Da

References

MacKinnon AC, Kilpatrick AT, Kenny BA, Spedding M, Brown CM: [3H]-RS-15385-197, a selective and high affinity radioligand for alpha 2-adrenoceptors: implications for receptor classification. Br J Pharmacol. 1992 Aug;106(4):1011-8. [PubMed:1327384]
Mitrani P, Srinivasan M, Dodds C, Patel MS: Role of the autonomic nervous system in the development of hyperinsulinemia by high-carbohydrate formula feeding to neonatal rats. Am J Physiol Endocrinol Metab. 2007 Apr;292(4):E1069-78. Epub 2006 Dec 12. [PubMed:17164433]
Lepretre N, Mironneau J: Alpha 2-adrenoceptors activate dihydropyridine-sensitive calcium channels via Gi-proteins and protein kinase C in rat portal vein myocytes. Pflugers Arch. 1994 Dec;429(2):253-61. [PubMed:7892112]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	185	N/A	N/A	7996470
Ki (nM)	239.88	N/A	N/A	9605427
Ki (nM)	31	N/A	N/A	1353247

Details3. Alpha-2C adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Agonist

General Function: Protein homodimerization activity
Specific Function: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins.
Gene Name: ADRA2C
Uniprot ID: P18825
Uniprot Name: Alpha-2C adrenergic receptor
Molecular Weight: 49521.585 Da

References

Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]

Property	Measurement	pH	Temperature (°C)	References
Ki (nM)	1778.28	N/A	N/A	9605427
Ki (nM)	213	N/A	N/A	2172775
Ki (nM)	2980	N/A	N/A	7996470
Ki (nM)	754	N/A	N/A	1353247

Details4. Alpha-2B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Binder

General Function: Epinephrine binding
Specific Function: Alpha-2 adrenergic receptors mediate the catecholamine-induced inhibition of adenylate cyclase through the action of G proteins. The rank order of potency for agonists of this receptor is clonidine...
Gene Name: ADRA2B
Uniprot ID: P18089
Uniprot Name: Alpha-2B adrenergic receptor
Molecular Weight: 49565.8 Da

References

Uhlen S, Wikberg JE: Delineation of rat kidney alpha 2A- and alpha 2B-adrenoceptors with [3H]RX821002 radioligand binding: computer modelling reveals that guanfacine is an alpha 2A-selective compound. Eur J Pharmacol. 1991 Sep 17;202(2):235-43. [PubMed:1666366]
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]

Details5. Alpha-1B adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Agonist

General Function: Protein heterodimerization activity
Specific Function: This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...
Gene Name: ADRA1B
Uniprot ID: P35368
Uniprot Name: Alpha-1B adrenergic receptor
Molecular Weight: 56835.375 Da

References

Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]

Details6. Alpha-1D adrenergic receptor

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Agonist

General Function: Alpha1-adrenergic receptor activity
Specific Function: This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name: ADRA1D
Uniprot ID: P25100
Uniprot Name: Alpha-1D adrenergic receptor
Molecular Weight: 60462.205 Da

References

Haenisch B, Walstab J, Herberhold S, Bootz F, Tschaikin M, Ramseger R, Bonisch H: Alpha-adrenoceptor agonistic activity of oxymetazoline and xylometazoline. Fundam Clin Pharmacol. 2010 Dec;24(6):729-39. doi: 10.1111/j.1472-8206.2009.00805.x. [PubMed:20030735]
Akinaga J, Lima V, Kiguti LR, Hebeler-Barbosa F, Alcantara-Hernandez R, Garcia-Sainz JA, Pupo AS: Differential phosphorylation, desensitization, and internalization of alpha1A-adrenoceptors activated by norepinephrine and oxymetazoline. Mol Pharmacol. 2013 Apr;83(4):870-81. doi: 10.1124/mol.112.082313. Epub 2013 Jan 30. [PubMed:23364786]
Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP: ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012 Jan;40(Database issue):D1100-7. doi: 10.1093/nar/gkr777. Epub 2011 Sep 23. [PubMed:21948594]

Drug created on June 13, 2005 07:24 / Updated on August 15, 2018 09:46

Oxymetazoline

Identification

Structure for DB00935 (Oxymetazoline)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

References

References

References